ARTV·Nasdaq·US
Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical-stage biotechnology company developing off-the-shelf natural killer cell therapies for autoimmune diseases and cancers. Its lead program is AlloNK, an allogeneic NK cell therapy in clinical development, supported by a manufacturing platform for producing cryopreserved cell-therapy product candidates.
Recent Activity
Updated Oct 31, 2026
–Artiva Biotherapeutics will lay off most of its staff and stop developing its experimental natural killer cell therapy for autoimmune conditions after reporting patient deaths.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.